References in periodicals archive ?
Despite the questionable validity of the initial discovery, delivering KIF6 genetic test results and expected statin benefits was associated with improved adherence and persistence to statin therapy in a nonrandomized study (14).
Matthew Taylor recently discussed the "step backward" that occurred in genetic risk prediction of coronary artery disease with the discovery that variations in the KIF6 gene might not be clinically associated with CAD after all.
Matthew Taylor discussed the "step backward" that occurred in genetic risk prediction of coronary artery disease (CAD) with the discovery that variations in the KIF6 gene might not be clinically associated with CAD after all.
One study found that once KIF6 is identified, the added risk can be lowered by using Bristol-Myers Squibb Co.
Biomarkers discussed in the report include: Cytochrome P450 and Drug Metabolism, Estrogen Receptor and Progesterone, Receptor Status for Breast Cancer, HER2 Overexpression and Herceptin and Tykerb, Epidermal Growth Factor Receptor (EGFR), KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer, BRAF Mutations and Cancer Therapy, UGT1A1 Genetic Variants, 5-Flurouracil Therapy, PIK3CA Genetic Variation, KIF6 Genetic Variation, ALK Genetic Variation.
As the evidence accumulated for KIF6's role, companies began to look at the development of clinical assays that culminated in a KIF6 genetic-testing assay that was marketed to cardiologists and internists.
Celera Corporation (NASDAQ:CRA) today provided an update on recent scientific findings pertaining to the KIF6 gene variant and its pre-market approval application (PMA) with the United States Food and Drug Administration (FDA) for its KIF6 Genotyping Assay.
Food and Drug Administration (FDA) for its KIF6 Genotyping Assay, a new molecular In Vitro diagnostic (IVD) test designed to detect a marker for risk of coronary heart disease (CHD) independent of traditional risk factors and aid clinical evaluation when statin treatment is being considered.
In September, Celera signed an agreement with Abbott for distribution of a CE-marked KIF6 test to identify patients at risk of coronary heart disease that is reduced with statin therapy.
Findings Also Show No Significant Difference from Earlier Published Reports by Celera and Others on Case-Control Studies of KIF6
Celera Corporation (NASDAQ:CRA) today announced that the United States Patent and Trademark Office has issued United States Patent 7,799,530 relating to methods of determining heart attack risk by detecting the KIF6 gene variant and reduction of such increased risk by statin therapy.
Celera Corporation (NASDAQ:CRA) and Abbott (NYSE:ABT) today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000[TM] instrument system.
Medical browser ?
- Kikuchi disease
- Kikuchi lymphadenitis
- Kikuchi, Ichiro
- Kikuchi, M.
- Kikuchi's disease
- Kikuchi's lymphadenitis
- Kikuth's disease
- kikuyu grass
- Kilham rat virus
- Kilian line
- Kilian pelvis
- Kilian, Hermann F.
- Kiliani, H.
- Kiliani-Fischer synthesis
- killed vaccine
- killer bee
- Killer bees
Full browser ?
- KIF26A variant protein
- KIF3-related motor protein
- KIF3C variant protein
- KIF5A variant protein
- Kigali Institute of Health
- Kigali Institute of Science and Technology
- Kigali Weapon Secure Area
- Kigali, Rwanda
- Kigali, Rwanda
- Kigali, Rwanda